Business
The Vaccine Group wins Department of Health grant
The Vaccine Group wins Department of Health grant.
About this update from Frontier Ip Group Plc
[{"type":"text","content":"\n \nRNS Number : 0673O Frontier IP Group plc 25 January 2019 \n\nRNS REACH / RNS\nAIM: FIPP\n25 January 2019\n \nFrontier IP Group Plc\n(\"Frontier IP\" or the \"Group\")\n \n \nPortfolio news - The Vaccine Group wins Department of Health and Social Care grant to combat antimicrobial-resistant disease\n \n \n \nFrontier IP, a specialist in commercialising university intellectual property, today announces portfolio company The Vaccine Group (\"TVG\" or the \"Company\"), has won a £403,000 grant as part of a £1.46 million Anglo-Chinese project to combat an emerging antibiotic-resistant disease able to jump from pigs to humans with potentially fatal effect. \n \nThe project, funded by the Department of Health and Social Care (DHSC) and administered by Innovate UK, will develop TVG's novel herpesvirus-based platform technology to create a single-use vaccine for use in pigs. The work will be undertaken with Chinese partners, including the Shanghai Veterinary Research Institute at the Chinese Academy of Agricultural Science, and the Shanghai Jiao Tong University. A major producer of swine and poultry vaccines, the Pulike Biological Engineering Company, is the commercial partner.\n \nThe vaccine will target a bacterium called Streptococcus suis (S.suis), which can cause meningitis, blood poisoning, or septicaemia, as well as many other serious diseases in humans. Incidents have been rising globally and in Asia it is now classified as an emerging threat. The disease is currently treated with antibiotics, but there is growing evidence that S.suis is becoming resistant to them. Effective vaccines remove the need to use antibiotics in animals. \n \nThe University of Plymouth spin out was founded by Dr Michael Jarvis, Associate Professor of Immunology and Virology at the university's Institute of Translational and Stratified Medicine. Frontier IP holds a 19.2 per cent stake in the Company. \n \nTVG's technology is based on safe forms of herpesviruses, which occur in nearly all animals, including humans. The vaccines are created by modifying these viruses through inserting regions of the pathogen being targeted to stimulate immune responses against the disease. \n \nThe grant was awarded as part a bilateral research competition between the DHSC's Global antimicrobial resistance (A...